{"id":59735,"date":"2026-03-17T16:35:38","date_gmt":"2026-03-17T08:35:38","guid":{"rendered":"https:\/\/flcube.com\/?p=59735"},"modified":"2026-03-17T16:35:39","modified_gmt":"2026-03-17T08:35:39","slug":"cspc-pharma-secures-dual-nmpa-fda-approval-for-pde4b-inhaler-syh2059-first-in-class-ild-candidate-enters-global-clinical-development","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59735","title":{"rendered":"CSPC Pharma Secures Dual NMPA\u2011FDA Approval for PDE4B Inhaler SYH2059 \u2013 First\u2011in\u2011Class ILD Candidate Enters Global Clinical Development"},"content":{"rendered":"\n<p><strong>CSPC Pharmaceutical Group Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1093:HKG\">HKG: 1093<\/a>) announced that its <strong>highly selective PDE4B inhibitor SYH2059 powder for inhalation<\/strong>, a <strong>Category 1 innovative chemical drug<\/strong>, has obtained <strong>clinical trial approval<\/strong> from China&#8217;s <strong>NMPA<\/strong> for <strong>interstitial lung disease (ILD)<\/strong> while simultaneously receiving <strong>FDA IND clearance<\/strong> for US clinical development, positioning the asset for parallel China\u2011US Phase I execution.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>SYH2059 powder for inhalation<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Category 1 innovative chemical drug (NMPA); novel NCE (FDA)<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td>Highly selective <strong>PDE4B<\/strong> (phosphodiesterase 4B)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Interstitial lung disease (ILD)<\/td><\/tr><tr><td><strong>China Approval<\/strong><\/td><td>NMPA clinical trial approval \u2013 16\u202fMar\u202f2026<\/td><\/tr><tr><td><strong>US Approval<\/strong><\/td><td>FDA IND clearance \u2013 March 2026<\/td><\/tr><tr><td><strong>IP Status<\/strong><\/td><td>Complete independent intellectual property rights (CSPC\u2011owned)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>SYH2059<\/strong> \u2013 novel, highly active, highly selective <strong>PDE4B inhibitor<\/strong><\/li>\n\n\n\n<li><strong>Formulation:<\/strong> <strong>Powder for inhalation<\/strong> \u2013 pulmonary delivery optimization<\/li>\n\n\n\n<li><strong>Selectivity Profile:<\/strong> PDE4B\u2011targeted vs. pan\u2011PDE4 inhibition (distinguishes from approved PDE4 inhibitors like roflumilast\/apremilast)<\/li>\n\n\n\n<li><strong>Delivery Advantage:<\/strong><\/li>\n\n\n\n<li><strong>Increased pulmonary drug concentration<\/strong> at site of action<\/li>\n\n\n\n<li><strong>Reduced systemic exposure<\/strong> \u2192 minimized gastrointestinal adverse effects (key limitation of oral PDE4 inhibitors)<\/li>\n\n\n\n<li><strong>Preclinical Efficacy:<\/strong> Superior to existing ILD therapeutics in animal disease models<\/li>\n\n\n\n<li><strong>PK\/Safety:<\/strong> Favorable pharmacokinetic profile with broad therapeutic index<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-differentiation-amp-competitive-context\">Strategic Differentiation &amp; Competitive Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Dimension<\/th><th>SYH2059 Position<\/th><th>Market Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>Target Selectivity<\/strong><\/td><td>PDE4B\u2011specific vs. pan\u2011PDE4<\/td><td>Potential to retain anti\u2011inflammatory efficacy while avoiding GI toxicity that limits oral PDE4 inhibitor compliance<\/td><\/tr><tr><td><strong>Route of Administration<\/strong><\/td><td>Inhalation (topical pulmonary)<\/td><td>Direct lung delivery aligns with ILD pathophysiology; reduces systemic side effect burden<\/td><\/tr><tr><td><strong>Dual Regulatory Path<\/strong><\/td><td>Simultaneous NMPA + FDA IND<\/td><td>Enables global Phase I design with potential for harmonized development; accelerates timeline vs. sequential filings<\/td><\/tr><tr><td><strong>IP Control<\/strong><\/td><td>Full CSPC ownership<\/td><td>Unencumbered global rights support partnership flexibility at Phase I\/II data inflection point<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>ILD Therapeutic Gap:<\/strong> Interstitial lung diseases (including idiopathic pulmonary fibrosis, connective tissue disease\u2011associated ILD) represent high\u2011unmet\u2011need indications with limited approved options (pirfenidone, nintedanib); PDE4B inhibition offers novel anti\u2011inflammatory\/fibrotic mechanism distinct from current antifibrotics.<\/li>\n\n\n\n<li><strong>PDE4 Inhibitor Market Context:<\/strong> Approved pan\u2011PDE4 inhibitors (roflumilast in COPD, apremilast in psoriasis) generate >US$2 billion annually but are constrained by nausea\/diarrhea discontinuation rates of 15\u201125%; SYH2059&#8217;s inhalation route and PDE4B selectivity address this compliance bottleneck.<\/li>\n\n\n\n<li><strong>CSPC Pipeline Validation:<\/strong> SYH2059 represents second respiratory inhalation asset in CSPC&#8217;s innovative portfolio, validating inhaled formulation capabilities and pulmonary therapeutic focus; dual NMPA\u2011FDA approval demonstrates regulatory affairs sophistication for global development.<\/li>\n\n\n\n<li><strong>Clinical Catalyst Timeline:<\/strong> Phase I initiation expected Q2\u2011Q3 2026 in both jurisdictions; Phase I data readout (safety\/PK) anticipated H2 2027 with potential for Phase II ILD efficacy signals by 2028\u20112029.<\/li>\n\n\n\n<li><strong>Partnership Optionality:<\/strong> Full IP ownership positions CSPC for potential co\u2011development or ex\u2011US licensing transactions upon demonstration of Phase I safety and target engagement; ILD indication attracts specialty pharma and respiratory\u2011focused biotech interest.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, regulatory pathways, and commercial expectations for SYH2059. Actual results may differ due to risks including safety findings, competitive dynamics, and regulatory requirements in multiple jurisdictions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its highly selective PDE4B inhibitor SYH2059 powder&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,171,855],"class_list":["post-59735","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-cspc-pharmaceutical","tag-hkg-1093"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CSPC Pharma Secures Dual NMPA\u2011FDA Approval for PDE4B Inhaler SYH2059 \u2013 First\u2011in\u2011Class ILD Candidate Enters Global Clinical Development - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its highly selective PDE4B inhibitor SYH2059 powder for inhalation, a Category 1 innovative chemical drug, has obtained clinical trial approval from China&#039;s NMPA for interstitial lung disease (ILD) while simultaneously receiving FDA IND clearance for US clinical development, positioning the asset for parallel China\u2011US Phase I execution.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=59735\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CSPC Pharma Secures Dual NMPA\u2011FDA Approval for PDE4B Inhaler SYH2059 \u2013 First\u2011in\u2011Class ILD Candidate Enters Global Clinical Development\" \/>\n<meta property=\"og:description\" content=\"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its highly selective PDE4B inhibitor SYH2059 powder for inhalation, a Category 1 innovative chemical drug, has obtained clinical trial approval from China&#039;s NMPA for interstitial lung disease (ILD) while simultaneously receiving FDA IND clearance for US clinical development, positioning the asset for parallel China\u2011US Phase I execution.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=59735\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-17T08:35:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-17T08:35:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59735#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59735\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CSPC Pharma Secures Dual NMPA\u2011FDA Approval for PDE4B Inhaler SYH2059 \u2013 First\u2011in\u2011Class ILD Candidate Enters Global Clinical Development\",\"datePublished\":\"2026-03-17T08:35:38+00:00\",\"dateModified\":\"2026-03-17T08:35:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59735\"},\"wordCount\":526,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"CSPC Pharmaceutical\",\"HKG: 1093\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59735#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59735\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=59735\",\"name\":\"CSPC Pharma Secures Dual NMPA\u2011FDA Approval for PDE4B Inhaler SYH2059 \u2013 First\u2011in\u2011Class ILD Candidate Enters Global Clinical Development - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-17T08:35:38+00:00\",\"dateModified\":\"2026-03-17T08:35:39+00:00\",\"description\":\"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its highly selective PDE4B inhibitor SYH2059 powder for inhalation, a Category 1 innovative chemical drug, has obtained clinical trial approval from China's NMPA for interstitial lung disease (ILD) while simultaneously receiving FDA IND clearance for US clinical development, positioning the asset for parallel China\u2011US Phase I execution.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59735#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59735\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59735#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CSPC Pharma Secures Dual NMPA\u2011FDA Approval for PDE4B Inhaler SYH2059 \u2013 First\u2011in\u2011Class ILD Candidate Enters Global Clinical Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CSPC Pharma Secures Dual NMPA\u2011FDA Approval for PDE4B Inhaler SYH2059 \u2013 First\u2011in\u2011Class ILD Candidate Enters Global Clinical Development - Insight, China&#039;s Pharmaceutical Industry","description":"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its highly selective PDE4B inhibitor SYH2059 powder for inhalation, a Category 1 innovative chemical drug, has obtained clinical trial approval from China's NMPA for interstitial lung disease (ILD) while simultaneously receiving FDA IND clearance for US clinical development, positioning the asset for parallel China\u2011US Phase I execution.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=59735","og_locale":"en_US","og_type":"article","og_title":"CSPC Pharma Secures Dual NMPA\u2011FDA Approval for PDE4B Inhaler SYH2059 \u2013 First\u2011in\u2011Class ILD Candidate Enters Global Clinical Development","og_description":"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its highly selective PDE4B inhibitor SYH2059 powder for inhalation, a Category 1 innovative chemical drug, has obtained clinical trial approval from China's NMPA for interstitial lung disease (ILD) while simultaneously receiving FDA IND clearance for US clinical development, positioning the asset for parallel China\u2011US Phase I execution.","og_url":"https:\/\/flcube.com\/?p=59735","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-17T08:35:38+00:00","article_modified_time":"2026-03-17T08:35:39+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=59735#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=59735"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CSPC Pharma Secures Dual NMPA\u2011FDA Approval for PDE4B Inhaler SYH2059 \u2013 First\u2011in\u2011Class ILD Candidate Enters Global Clinical Development","datePublished":"2026-03-17T08:35:38+00:00","dateModified":"2026-03-17T08:35:39+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=59735"},"wordCount":526,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","CSPC Pharmaceutical","HKG: 1093"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=59735#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=59735","url":"https:\/\/flcube.com\/?p=59735","name":"CSPC Pharma Secures Dual NMPA\u2011FDA Approval for PDE4B Inhaler SYH2059 \u2013 First\u2011in\u2011Class ILD Candidate Enters Global Clinical Development - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-17T08:35:38+00:00","dateModified":"2026-03-17T08:35:39+00:00","description":"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its highly selective PDE4B inhibitor SYH2059 powder for inhalation, a Category 1 innovative chemical drug, has obtained clinical trial approval from China's NMPA for interstitial lung disease (ILD) while simultaneously receiving FDA IND clearance for US clinical development, positioning the asset for parallel China\u2011US Phase I execution.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=59735#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=59735"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=59735#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CSPC Pharma Secures Dual NMPA\u2011FDA Approval for PDE4B Inhaler SYH2059 \u2013 First\u2011in\u2011Class ILD Candidate Enters Global Clinical Development"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59735","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=59735"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59735\/revisions"}],"predecessor-version":[{"id":59736,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59735\/revisions\/59736"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=59735"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=59735"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=59735"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}